SparX Biopharmaceutical Corp, a US research-based development-stage biopharmaceutical company, announced on Tuesday that it has named Dr Roland Meier as its new chief medical officer.

Dr Meier has more than two decades of experience, with extensive expertise in oncology drug development, commercial launch and life-cycle management. He has served in significant leadership positions, notably as executive medical director at Kyowa Kirin and vice president of Immuno-Oncology at Eli Lilly.

Dr Guidong Zhu, SparX CEO and founder, said: "Dr. Meier's esteemed reputation in immuno-oncology drug development is unparalleled. As SparX continues to advance our comprehensive discovery technology platforms, spanning from target-mining to biologics drug discovery and production, Roland's profound expertise and leadership in tumor biology become indispensable. He is renowned not just for his contributions to all stages of immuno-oncology drug development, but also for his innovative spirit and discerning perspective on strategic immuno-oncological initiatives. With Roland on board, we are poised to transition SparX from a discovery-centric to a clinical-driven biotech entity."